Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 14/20 | 0.52 |
| ▸ | CLK1 | P49759 | 3/20 | 0.49 |
| ▸ | CLK2 | P49760 | 3/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485455 | 0.83 | CLK1 (0.71) | MAP3K5CLK1CLK2RETCDK2 | |
| SCHEMBL3486104 | 0.80 | MAP3K5 (0.66) | MAP3K5CLK1CLK2RETCDK2 | |
| SCHEMBL3485629 | 0.78 | MAP3K5 (0.77) | MAP3K5CLK1CLK2RETCDK2 | |
| SCHEMBL3486260 | 0.78 | MAP3K5 (0.56) | MAP3K5CLK1CLK2RETCDK2 | |
| SCHEMBL13498799 | 0.77 | MAP3K5 (0.55) | MAP3K5CLK1CLK2RETCDK2 | |
| SCHEMBL3486448 | 0.77 | MAP3K5 (0.56) | MAP3K5CLK1CLK2MAPTRET | |
| SCHEMBL3486382 | 0.76 | MAP3K5 (0.54) | MAP3K5CLK1CLK2RETCDK2 | |
| SCHEMBL3136496 | 0.76 | MAP3K5 (0.45) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3146108 | 0.75 | PIK3CA (0.72) | MAP3K5CLK1CLK2CSNK1DCSNK1E | |
| SCHEMBL3146263 | 0.75 | MAP3K5 (0.47) | MAP3K5LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | MAP3K5 192/4885CLK1 750/4885CLK2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.